• Strafford #1Strafford will be offering a webinar entitled "Patent Drafting for Machine Learning: Structural Claim Limitations, Avoiding §101 or §112 Rejections" on February 13, 2018 from 1:00 to 2:30 pm (EST).  Gregory Rabin of Schwegman Lundberg & Woessner and Michael D. Stein of Baker & Hostetler will provide guidance to patent practitioners on overcoming the challenges when seeking patent protection for machine learning inventions, and also discuss what can be done to anticipate and minimize the risks of § 101 or § 112 rejections.  The webinar will review the following issues:

    • What hurdles must patent counsel overcome to demonstrate inventorship?
    • How can patent counsel meet the requirements under § 101 and § 112 in machine learning patent applications?
    • What steps should patent counsel take to minimize the likelihood of § 101 or § 112 rejections?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.

  • JMLSThe John Marshall Law School Center for Intellectual Property, Information & Privacy Law will be hosting Richard S. Gruner, former Director, Center for Intellectual Property Law, John Marshall Law School, who will be giving a presentation entitled "Classes without Quizzes – Invention, Imagination & Patent Incentives" from 4:00 to 5:30 pm (CST) on February 2, 2018 at the John Marshall Law School in Chicago, IL.  The presentation is about three things: imagination, invention, and shaping patent law incentives, topics that are seemingly disparate but which are actually linked subjects.

    There is no registration fee for the presentation.  Those interested in registering for the pre4sentation can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Sect. 112 Indefiniteness in Chemical and Biotech Patent Claims — Drafting and Prosecuting Patent Claims That Will Hold Up Under Any Definiteness Standard" on February 14, 2018 from 1:00 to 2:30 pm (EST).  Thomas L. Irving and Amanda K. Murphy of Finnegan Henderson Farabow Garrett & Dunner, and Amelia Feulner Baur of McNeill Baur will provide guidance to patent counsel on the impact of recent Federal Circuit and PTAB case law on daily patent practice, and offer best practices to navigate pre- and post-issuance scrutiny for compliance with 35 U.S.C. § 112(b).  The webinar will review the following issues:

    • How do the decisions distinguish the USPTO’s standard and the court’s standard for indefiniteness?
    • What are the implications of the post-Nautilus and post-Packard/McAward cases for patent counsel in drafting applications?
    • What steps can counsel take to increase the likelihood that patent claims will survive in litigation and under PTAB review?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.

  • By Andrew Williams

    USPTO SealIn November, Chief Judge David P. Ruschke of the U.S. Patent and Trademark Office's Patent Trial and Appeal Board issued a memorandum entitled "Guidance on Motions to Amend in view of Aqua Products" (see "PTAB Motions to Amend Post-Aqua Products — Chief Judge Ruschke Issues Guidance").  The bottom line of this guidance was that the "practice and procedure before the Board will not change," except in the rare situation in which the "entirety of the evidence of record before the Board in in equipoise as to the unpatentability of one or more substitute claims."  But how has Aqua Products impacted specific motions to amend?  We received some indication in December when a three-judge panel granted-in-part a motion to amend in Taiwan Semiconductor Manufacturing Co. v. Godo Kaisha IP Bridge (IPR2016-01249).  The Board in that case found that:  (1) the motion to amend did not include an unreasonable number of substitute claims, (2) substitute claim 13 was not broader than the scope of the challenged claims, (3) claim 13 did not introduce new matter, and (4) claim 13 responded to a ground of unpatentability in the proceeding.  The other two substitute claims, claims 11 and 12, were found to be unpatentable over the prior art of record because the newly introduced limitations were found to be "met by the very references asserted in the ground of unpatentability involved in" the IPR.  APJ Michael J. Fitzpatrick joined this per curiam decision, but he wrote separately because he believed the decision should have informed which party bears what burden(s) with respect to the Motion to Amend.

    IPR2016-01249 was directed to U.S. Patent No. 6,538,324, which "relates to a semiconductor integrated circuit including a copper wiring layer, and more particularly to a barrier film which prevents copper diffusion from such a copper wiring layer."  Without going into the details, the only ground instituted in this IPR proceeding was that specific claims of the '324 patent were obvious over U.S. Patent No. 6,887,353 (Ding) in view of U.S. Patent No. 5,893,752 (Zhang).  On December 20, 2017, the Board issued its final written decision in which it found that the petitioner had met its burden of showing the relevant claims would have been obvious over Ding and Zhang.  However, the Patent Owner filed its motion to amend proposing substituting claims 11-13 for issued claims 5, 8, and 7, respectively.  The Board pointed out that "[a] motion to amend must meet the requirements set forth in 35 U.S.C. § 316(d) and 37 C.F.R. § 42.121."  However, it noted that Aqua Prods., Inc. v. Matal held that "[a] patent owner does not have a burden to prove its substitute claims are patentable under 35 U.S.C. §§ 102 and 103," although the Board pointed out that 35 U.S.C. § 318(a) still requires that patentability be an issue in deciding the motion.

    One of the reasons that this case is noteworthy is the way that the Board handled substitute claim 13.  Because it depended from substitute claim 11, we include both for reference:

    11.  (Substitute for claim 5) A multi-layered wiring structure comprising a barrier film which prevents diffusion of copper from a copper wiring layer formed on a semiconductor substrate,
        said barrier film having a multi-layered structure of first and second films,
        said first film being composed of crystalline metal containing nitrogen therein, the nitrogen being present throughout the first film,
        said second film being composed of amorphous metal nitride,
        said barrier film being constituted of common metal atomic species,
        said first film being formed on said second film,
        said first film in direct contact with said second film,
        said first film containing nitrogen in a smaller content than that of said second film.

    13.  (Substitute for claim  7) The  multi-layered wiring structure as set forth in claim [[5]] 11, wherein said first film has a thickness in the range of 60 angstroms to 300 angstroms both inclusive;
        wherein said first film being composed of crystalline metal containing nitrogen therein is a solid solution; and
        a copper film is formed on and in direct contact with said first film.

    Interestingly, eight days before the final written decision, on December 12, 2017, the Board issued an Order suggesting that they "intend[ed] to grant the Motion to Amend with respect to claim 13 in a forthcoming final written decision."  However, the Board indicated that this intent was conditional on the Patent Owner re-presenting claim 13 in independent form, and more importantly replacing each instance of "being composed of" with the phrase "consisting essentially of."  This was because the Patent Owner had argued that the former means the latter.  For whatever reason, the Patent Owner chose not file the additional requested paper.  Nevertheless, the Board still allowed the substitution of claim 13 with the caveat that "[f]or purposes deciding the merits of the Motion to Amend as it relates to claim 13, [they] treated[ed] each instance of 'being composed of,' including those in claim 11 from which claim 13 depends, as Patent Owner asserts, to mean 'consisting essentially of.'"  It will be interesting to see if other panels take a similar approach and provide guidance as to which claims might survive a Motion to Amend, and whether future panels will provide the Patent Owner with the opportunity to make changes to the proposed claims.

    As indicated above, APJ Fitzpatrick joined the per curiam decision, but he wrote separately.  He felt that the decision did not disclose who bears the burden(s), and therefore future "patent owners will be left guessing what their motion to amend must contain."  Therefore, he would have explicitly held that:  "the Motion to Amend is granted with respect to proposed claim 13 because Patent owner met its burden or production to show that claim 13 complies with the statutory and regulatory requirements for motions to amend, and because Petitioner did not meet its burden to prove by a preponderance of the evidence that claim 13 is unpatentable."  In fact, he made clear that he would place the burden of production on petitioners because the statute and rule do not mention novelty, non-obviousness, or patentability generally (citing 25 U.S.C. § 316(d) and 37 C.F.R. § 42.121).  Moreover, he indicated that he would also place the burden of persuasion on petitioners "because doing so is consistent with the most relevant statutory provision and there is no applicable rule requiring otherwise."  There were two caveats to these rules.  First, he believes that the burden on production should be on the patent owner to show that the written description requirement has been met, because (among other reasons) 35 U.S.C. § 316(d)(3) states that "[a]n amendment . . . may not . . . introduce new matter."  Unfortunately, this statement may be at odds with the Federal Circuit's statement in Bosch Automotive Service Solution, LLC v. Matal, decided two days later on December 22, 2017, in which the Court indicated that petitioner bears the burden of proving all aspects of unpatentability "by a preponderance of the evidence."  ("This burden of proof allocation applies to questions of indefiniteness, as with other questions of unpatentability.  The second was that he would place the burden of production on the patent owner to establish that a substitute claim is responsive to an instituted ground of unpatentability.)  This is based in his belief that Rule 42.20(c) was not overruled by Aqua Products, but that instead the Board's interpretation of the rule was as set forth in Idle Free and MasterImage.  Instead, he expressed his belief that "Rule 42.20(c)'s application to motions to amend should be more closely tethered to the statute and rule that explicitly address motions to amend, i.e., § 316(d) and rule 42.121."

    APJ Fitzpatrick also explained why putting the burden on the petitioner should not be a concern, even when it chooses not to oppose the motion to amend.  He pointed out that instead of ending up with any potential claim, the Patent Owner will still be restricted by the statute.  For example, "§ 316(d)(3) requires every substitute claim to be narrower than the challenged claim it is replacing."  Therefore, the public benefits by the resulting narrowing of claim scope.  In fact, § 316(d)(2) demonstrates Congress's belief that this is a public benefit, because it "permits parties to jointly request entry of a narrower claim to facilitate settlement."

    Of course, APJ Fitzpatrick's comments are not part of the decision in this case.  But they do at least shed some light on how on APJ is approaching motions to amend claims.  And they may be indicative of how other APJs will address these issues.  As a result, his concurrence may end up being the guidance that he believed Patent Owner deserved from any decision from Board on motions to amend.

  • By Kevin E. Noonan –

    Federal Circuit SealOne of the most important (if not the most important) inquiries in performing due diligence involving acquisition of a patent portfolio is ensuring that the entity asserting ownership of the patents actually has proper title (in what can be a complex chain, starting with the inventors).  This is particularly true in view of the position taken by the Federal Circuit that even one inventor, who has not assigned her rights, can prevent the other inventors or their assignee from bringing suit as being an indispensible party, and that the Federal Rules of Civil Procedure do not permit that recalcitrant inventor from being involuntarily joined.  The failure to make sure that the chain of title was intact led a district court to grant defendants' motion to dismiss, in Advanced Video Technologies LLC v HTC Corp., a decision the Federal Circuit affirmed last week.

    The dispute arose over U.S. Patent No. 5,781,788, which claimed a "full duplex single chip video codex."  As the opinion notes, "the technology of the patent is not at issue" — indeed the opinion says nothing more about the subject matter of the '788 patent.  Instead, the Federal Circuit's opinion (as with the District Court's opinion below) revolved around whether the plaintiff had standing to sue, in light of evidence that one of the inventors had not assigned away her rights to the claimed invention.

    The facts are, as could be expected, complicated.  The patent lists three inventors:  Beng-Yu "Benny" Woo, Xiaoming Li, and Vivian Hsiun, and the opinion states that these three co-inventors worked for Infochips Systems, Inc. at the time the invention was made.  Mr. Woo and Ms. Li duly assigned their rights to the invention to Infochips; Ms. Hsiun did not, despite the existence of a contractual obligation to assign, according to plaintiff AVT here.

    AVT's ownership in the patent in suit stems from a series of transfers having to do with business arrangements made by Infochips.  These include pledging Infochips' rights to the patent as security to a financing arrangement between Infochips and Leased Management Services (LMS), which seized the patent assets when Infochips went out of business in 1993.  (Whether this "seizure" was part of a bankruptcy or settlement of what Infochips owed LMS is unclear from the opinion.)  LMS then sold the patent asset to inventor Woo, who then assigned his ownership interest to AVC Technology, Inc.

    It was AVC that filed the "parent" application to the '788 patent, in 1995, and Mr. Woo and Ms. Li again executed assignments, this time to AVC.  (Of course, if the chain of title transfers is correct, these inventors had no rights left to assign by this point.  The title transfers also illustrate the bygone world of a patent having a term of 17 years from grant:  under present law, the patents would have expired in 2016 at the latest.)  Regarding Ms. Hsiun, this time she affirmatively refused to assign her rights.  The U.S. Patent and Trademark Office permitted AVC to prosecute the parent patent that ultimately issued (as a continuation) as the '788 patent, based on AVC's petition supported by the Infochips Employment agreement and documents showing the chain of title culminating in AVC's purported ownership.  Ownership in the patent was further transferred until it finally came to rest with the AVT plaintiff here.

    The case at bar first arose in a lawsuit between the parties named in this case, filed in 2011 but dismissed due to failure to comply with Delaware law relating to how assets of dissolved corporations are distributed, wherein the patent ownership rights were not transferred to AVT (the error being sufficiently egregious that the District Court awarded attorneys' fees to defendants under 35 U.S.C. § 285).  AVT corrected this error in title before the Delaware Chancery Court, and then refiled its lawsuit against the HTC defendants.  The District Court's decision and this appeal followed.

    The basis for Defendant HTC's motion to dismiss being failure of inventor Hsiun to assign her rights, AVT asserted three portions of the employment between Ms. Hsiun and Infochips:  "a 'will assign' provision, a trust provision, and a quitclaim provision," as follows:

    I agree that I will promptly make full written disclosure to the Company, will hold in trust for the sole right and benefit of the Company, and will assign to the Company all my right, title, and interest in and to any and all inventions, original works of authorship, developments, improvements or trade secrets which I may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice, during the period of time I am in the employ of the Company.

    (the "will assign" and "trust" provisions; emphasis in opinion); and

    I hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, which I now or may hereafter have infringement [sic] of any patents, copyrights, or mask work rights resulting from any such application assigned hereunder to the Company.

    (the "quitclaim" provision; emphasis in opinion).

    The District Court was unconvinced that these provisions "effect[ed] a transfer" of inventor Hsiun's ownership rights in the patent, and accordingly dismissed the complaint.  Specifically, Judge McMahon on the bench in the Southern District of New York dismissed AVT's complaint for lack of standing, finding that Ms. Hsiun was a co-owner of the patent in suit and that she had not assigned her rights to plaintiff's predecessor in interest.

    The Federal Circuit affirmed, in an opinion by Judge Reyna, joined by Judge O'Malley who wrote a concurring opinion.  Judge Newman dissented.  The Court reviewed the District Court's analysis of each of the asserted terms of the Infochips Employment agreement and came to the same conclusion regarding their ineffectiveness in transferring inventor Hsiun's ownership rights to Infochips (and hence, to plaintiff AVT).

    With regard to the "will assign" provision, the panel agreed with the District Court that this provision merely "invoked a promise to do something in the future and did not effect a present assignment," relying on Arachnid, Inc. v. Merit Industries, Inc., 939 F.2d 1574, 1576 (Fed. Cir. 1991) (also consistent with the Supreme Court's opinion in another context, in Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems, Inc. (2011)).  And the purported "trust" provision supported this interpretation, according to both the District Court and Federal Circuit, because Ms. Hsiun could not simultaneously assign her rights and hold them in trust for her employer.

    The District Court further analyzed the trust provision in light of California law, which AVT argued created an "immediate trust" in favor of Infochips.  Even if this is the case, the District Court concluded (and the Federal Circuit agreed) that there was no evidence that Ms. Hsiun ever transferred her interest from any such trust to Infochips, thus not providing any basis to find in AVT's favor.  And the opinion cites precedent (Jim Arnold Corp. v. Hydrotech Sys., 109 F.3d 1567, 1578 (Fed. Cir. 1997)) that the proper order of asserting AVT's claim was to first bring an action against inventor Hsiun (in state court) to enforce the employment agreement, and only then (if successful) suing defendant HTC.  Which of course AVT never did.  In addition (and a point upon which the majority differs with Judge Newman), under California law a trust beneficiary "'generally is not the real party in interest,' 'may not sue in the name of the trust,' and 'has no legal title or ownership interest in the trust assets,'" citing relevant California decisions.

    Finally, with regard to the quitclaim assignment argument, AVT advanced the interpretation that the language "assigned hereunder" should be taken to mean "assignable hereunder"; not surprisingly, neither the District Court nor the Federal Circuit was convinced.  Both courts understood the provision to apply to Ms. Hsiun's ownership rights to any patents she had actually assigned, but that did not occur and thus this provision does not apply to the claims at issue before the court.

    The majority opinion responded to Judge Newman's dissent, that the Employment Agreement language "intended" to have Ms. Hsiun's ownership interest in any patents be assigned to and owned by Infochips by stating that the agreement by its terms does not so provide, and that California courts have held that they "should not deviate from unambiguous provisions unless they lead to 'absurd results.'"

    Judge O'Malley's concurrence sets forth her view that, while binding Federal Circuit precedent mandates the majority's result, she believes that precedent is wrongly decided.  In particular, she takes issue with the standard that "a non-consenting co-owner or co-inventor can never be involuntarily joined in an infringement action pursuant to Rule 19 of the Federal Rules of Civil Procedure."  In this she hales back to her dissent in STC.UNM v. Intel Corp., 767 F.3d 1351 (Fed. Cir. 2014), with regard to Rule 19.  Specifically,  she believes that Rule 19(a) mandates that anyone who is a mandatory party must be joined in order for a case to proceed.  Further, she believes it settled law that the Federal Rules are "as binding as any Federal statute," citing Stone Container Corp. v. United States, 229 F.3d 1345, 1354 (Fed. Cir. 2000), and that they apply to patent cases as to all other cases brought in Federal Court, citing somewhat mischievously eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388, 393–94 (2006).  And she sets forth her belief that it is the Federal Rules, rather than "substantive judge-made laws governing joinder" that govern the question before the Court.

    With that as prelude, she sets forth her opinion that Rule 19(a) provides for involuntary joinder of a necessary party, setting forth the Rule in the text of her opinion and in particular Rule 19(a)(2):

    (2) Joinder by Court Order.  If a person has not been joined as required, the court must order that the person be made a party.  A person who refuses to join as a plaintiff may be made either a defendant or, in a proper case, an involuntary plaintiff.

    In Judge O'Malley's view:

    There is no dispute over whether co-owners are necessary parties to infringement actions; the question we must address is whether a co-owner's mere recalcitrance can prevent enforcement of another co-owner's rights.  Rule 19(a) is designed to address circumstances just like those at issue here.

    And in her opinion, the Rule certainly is so designed.  She expressly rejects what she characterizes as dicta from Ethicon, Inc. v. U.S. Surgical Corp., 135 F.3d 1456 (Fed. Cir. 1998), the idea that Federal Circuit precedent precludes using Rule 19 to effect involuntary joinder in patent cases, setting forth an "[e]xamination of the pertinent case law" that includes Ethicon as well as Schering Corp. v. Roussel-UCLAF SA, 104 F.3d 341, 345 (Fed. Cir. 1997), and an earlier case relied upon by the Schering panel, Willingham v. Lawton, 555 F.2d 1340 (6th Cir. 1977).  As explicated by Judge O'Malley, none of these cases support the view apparently held by her brethren (as evidenced by DDB Techs., L.L.C. v. MLB Advanced Media, L.P., 517 F.3d 1284, 1289 n.2 (Fed. Cir. 2008)) that a recalcitrant inventor can preclude an assignee or co-inventors from bringing suit.  Moreover, Judge O'Malley perceives that, prior to its STC.UNM v. Intel Corp. decision, the Federal Circuit had "never explicitly held that one patent co-owner cannot involuntarily join the other."

    Finally, Judge O'Malley cites § 281 of the Patent Act, to the effect that "[a] patentee shall have remedy by civil action for infringement of his patent," as being inconsistent with the Court's opinions in STC.UNM v. Intel Corp. and here, that one inventor can preclude co-inventors or their assignee(s) from enforcing a patent without the inventor's permission.

    In her dissent, Judge Newman sets forth a detailed analysis of the Employment Agreement, which in her view taken in toto supports AVT's position that the agreement operates to vest title of Ms. Hsiun's interest in the patent in her employer Infochips (and through the series of transfers set forth above and in the opinion now rest with AVT).  She also characterizes HTC's argument as a litigation stratagem developed by defendants and supported by no assertion by Ms. Hsiun that she has refused to assign her rights (other than by her refusal to execute a standard assignment document).  And to the extent prior Federal Circuit case law applies, she distinguishes both Ethicon Inc. v. U.S. Surgical Corp. and Arachnid, Inc. v. Merit Industries, Inc. on their facts and disagrees with both Judges Reyna and O'Malley that the majority's decision is mandated by the Court's ruling in either of those cases.

    Advanced Video Technologies LLC v. HTC Corp. (Fed. Cir. 2018)
    Panel: Circuit Judges Newman, O'Malley, and Reyna
    Opinion by Circuit Judge Reyna; concurring opinion by Circuit Judge O'Malley; dissenting opinion by Circuit Judge Newman

  • By John Cravero

    USPTO SealAbout the PTAB Life Sciences Report:  Each month we will report on developments at the PTAB involving life sciences patents.

    Micro Labs Ltd. v. Santen Pharmaceutical Co.

    PTAB Petition:  IPR2017-01434; filed May 12, 2017.

    Institution of Inter Partes Review; entered November 29, 2017.

    Patent at Issue:  U.S. Patent No. 5,886,035 ("Difluoroprostaglandin derivatives and their use," issued March 23, 1999) claims a fluorine-containing prostaglandin derivative of formula (1) or a salt thereof.

    Petitioners Micro Labs Ltd. and Micro Labs USA Inc. are challenging the '035 patent on two grounds as obvious under 35 U.S.C. § 103(a).  View the petition here.  Administrative Patent Judges Lora M. Green, Jo-Anne M. Kokoski (author), and Christopher G. Paulraj issued a decision instituting inter partes review of whether claims 1-14 are unpatentable under 35 U.S.C. § 103(a) over Klimko, Kishi, and Ueno; and whether claims 1-14 are unpatentable under 35 U.S.C. § 103(a) over Klimko, Kishi, Bezuglov 1982 and/or Bezuglov 1986, and Ueno.

    Related Matters:  According to the petition, the '035 patent is the subject of the following litigations:  Santen Pharmaceutical Co., Ltd. v. Micro Labs Ltd., Case No. 16-cv-00353 (D. Del. 2016), and Santen Pharmaceutical Co., Ltd. v. Sandoz Inc., Case No. 16-cv-00354 (D. Del. 2016).


    Samsung Bioepis Co., Ltd. v. Genentech, Inc.

    PTAB Petition:  IPR2018-00192; filed November 30, 2017.

    Patent at Issue:  U.S. Patent No. 7,846,441 ("Treatment with anti-ErbB2 antibodies," issued December 7, 2010) claims a method for the treatment of a human patient with a malignant progressing tumor or cancer characterized by overexpression of ErbB2 receptor, comprising administering a combination of an intact antibody which binds to epitope 4D5 within the ErbB2 extracellular domain sequence and a taxoid, in the absence of an anthracycline derivative, to the human patient in an amount effective to extend the time to disease progression in said human patient, without increase in overall severe adverse events.

    Petitioner Samsung Bioepis Co. is challenging the '441 patent on two grounds as being obvious under 35 U.S.C. § 103(a).  View the petition here.

    Related Matters:  According to the petition, the European counterpart of '441 patent, EP 1,037,926, was invalidated and revoked as lacking inventive step in two proceedings:  (1) Hospira UK, Ltd. v. Genentech, Inc., No. HP-2014-000034, [2015] EWHC (HC) 1796 (Pat), (Jun. 24, 2015) (Ex. 1003), aff’d Hospira UK, Ltd. v. Genentech, Inc., No. A3 2015 3238, [2016] EWCA Civ 1185 (Nov. 30, 2016) (Ex. 1021); and (2) Decision to Revoke European Patent EP 1,037,926, Application No. 98,963,840.8 (Jun. 13, 2016) (Ex. 1020).

    Petitioner has identified several other inter partes review petitions on the '441 patent, including:  IPR2017-0073 (Hospira Inc.; U.S. Patent No. 7,846,441; filed 01/20/2017; denied 07/27/2017; instituted following request for rehearing 10/26/2017; pending); IPR2017-01121 (Celltrion, Inc.; U.S. Patent No. 7,846,441; filed 03/21/2017; Instituted 10/04/2017; pending); IPR2018-00016 (Pfizer Inc.; U.S. Patent No. 7,846,441; filed 10/03/2017; pending).  The Peition also identifies inter partes review petitions IPR2017-00737 (Hospira Inc.; U.S. Patent No. 7,892,549; filed 01/20/2017; instituted 07/27/2017; pending); IPR2017-00739 (Hospira Inc.; U.S. Patent No. 7,892,549; filed 01/20/2017; denied 07/27/2017); IPR2017-01122 (Celltrion Inc.; U.S. Patent No. 7,892,549; filed 03/21/2017; instituted 10/04/2017; pending); and IPR2017-01960 (Samsung Bioepis; U.S. Patent No. 7,892,549; filed 08/25/2017; pending).


    Trans Ova Genetics, LC. v. XY, LLC

    PTAB Petition:  IPR2018-00247; filed November 30, 2017.

    Patent at Issue:  U.S. Patent No. 7,723,116 ("Apparatus, methods and processes for sorting particles and for providing sex-sorted animal sperm," issued May 25, 2010) claims a method of flow cytometry sperm processing.

    Petitioner Trans Ova Genetics, LCC is challenging the '116 patent on four grounds as being obvious under 35 U.S.C. § 103(a).  View the petition here.

    Related Matters:  According to the petition, the '116 patent is the subject of the following litigation:  XY, LLC et al. v. Trans Ova Genetics, LC, No. 1:17-cv-00944 (D. Colo.).  Petitioner has filed a separate inter partes review petition on claims 42-59, 65-67, and 69 of the '116 patent (IPR2018-00248; filed 11/30/2017; pending).


    Trans Ova Genetics, LC. v. XY, LLC

    PTAB Petition:  IPR2018-00248; filed November 30, 2017.

    Patent at Issue:  U.S. Patent No. 7,723,116 ("Apparatus, methods and processes for sorting particles and for providing sex-sorted animal sperm," issued May 25, 2010) claims a method of flow cytometry sperm processing.

    Petitioner Trans Ova Genetics, LCC is challenging the '116 patent on four grounds as being obvious under 35 U.S.C. § 103(a).  View the petition here.

    Related Matters:  According to the petition, the '116 patent is the subject of the following litigation:  XY, LLC et al. v. Trans Ova Genetics, LCC, No. 1:17-cv-00944 (D. Colo.).  Petitioner has filed a separate inter partes review petition on claims 1-26, 33, 34, and 39-41 of the '116 patent (IPR2018-00247; filed 11/30/2017; pending).


    Roquette Frères, S.A. v. Tate & Lyle Ingredients Americas LLC

    PTAB Petition:  IPR2017-01506; filed May 30, 2017.

    Institution of Inter Partes Review; entered November 30, 2017.

    Patent at Issue:  U.S. Patent No. 7,608,436 ("Process for producing saccharide oligomers," issued October 27, 2009) claims a process for preparing saccharide oligomers, comprising: heating an aqueous feed composition that comprises at least one monosaccharide or linear saccharide oligomer, and that has a solids concentration of at least about 70% by weight, to a temperature of at least about 40oC.; and contacting the feed composition with at least one catalyst that accelerates the rate of cleavage or formation of glucosyl bonds for a time sufficient to cause formation of non-linear saccharide oligomers, wherein a product composition is produced that contains a higher concentration of non-linear saccharide oligomers than linear saccharide oligomers; wherein the product composition comprises non-linear saccharide oligomers having a degree of polymerization of at least three in a concentration of at least about 20% by weight on a dry solids basis.

    Petitioners Roquette Frères, S.A. are challenging the '436 patent on eight grounds as being anticipated under 35 U.S.C. § 102(b) (grounds 1, 3, and 5) or obvious under 35 U.S.C. § 103(a) (grounds 2, 4, and 6-8).  View the petition here.  Administrative Patent Judges Lora M. Green, Grace Karaffa Obermann (author), and Jacqueline T. Harlow issued a decision instituting inter partes review of whether claims 1-4, 15-18, 23-29, 31, and 32 are anticipated under 35 U.S.C. § 102(b) by Shah; whether claims 1-4, 15-18, 23-29, 31, and 32 are unpatentable under 35 U.S.C. § 103(a) over Shah and Craig; and whether claims 1-4, 15-18, 23-29, 31, and 32 are unpatentable under 35 U.S.C. § 103(a) over Shah, Craig, and Cleland.

    Related Matters:  According to the petition, the Petitioner concurrently filed a petition for inter partes review of related patent U.S. Patent No. 8,057,840 (IPR2017-01507; filed 05/30/2017; institution denied 11/30/2017).

  • By Michael Borella

    Wordlogic brought an action against Fleksy in the Northern District of Illinois, alleging infringement of U.S. Patent Nos. 7,681,124 and 8,552,984.  Flesky moved to dismiss the case under Rule 12(b)(6), on the grounds that the asserted claims lacked subject matter eligibility.  Presiding Judge Lefkow of the Northern District denied the motion.

    Wordlogic manufactures and sells iKnowU, a predictive keyboard application for mobile devices.  According to the Court, "[b]ased on the letters a user is typing, iKnowU predicts the next most likely letters, words, and phrases, allowing the user to complete the text she wishes to enter on the mobile device using fewer keystrokes."  This product is covered by claims of both patents-in-suit.  Flesky also manufactures and provides a predictive keyboard application, and Wordlogic alleged that this application infringed on claim 19 of the '124 patent and claim 1 of the '984 patent.

    As an example of these two claims, claim 19 recites:

    A computer-readable medium comprising codes for directing a processing unit to process text entered into a personal computing device, by:
        (a) receiving and displaying a partial text entry, comprising receiving at least part of the partial text entry via a keyboard, the partial text entry comprising at least a first character;
        (b) in response to receipt of the first character of the partial text entry, obtaining a plurality of completion candidates from among a group of completion candidates, wherein each of the plurality of completion candidates includes a portion matching the partial text entry;
        (c) displaying the plurality of completion candidates in a search list within a graphical user interface;
        (d) detecting user input corresponding to selection of a particular completion candidate from among the plurality of completion candidates displayed in the search list;
        (e) modifying the display of the partial text entry to correspond to the particular completion candidate selected from among the plurality of completion candidates at least while the particular completion candidate remains selected;
        (f) detecting modification of the partial text entry by the user via the keyboard;
        (g) obtaining and displaying in the search list a modified plurality of completion candidates from among the group of completion candidates, if the partial text entry is modified via the keyboard, wherein each of the modified plurality of completion candidates includes a portion matching the partial text entry; and
        (h) obtaining and displaying in the search list a further modified plurality of completion candidates from among the group of completion candidates, if a completion candidate is accepted via the search list from the modified plurality of completion candidates, wherein each of the further modified plurality of completion candidates includes a portion matching the accepted completion candidate.

    The Supreme Court's Alice Corp. v. CLS Bank Int'l case set forth a two-part test to determine whether claims are directed to patent-eligible subject matter under 35 U.S.C. § 101.  One must first decide whether the claim at hand is directed to a judicially-excluded law of nature, a natural phenomenon, or an abstract idea.  If so, then one must further decide whether any element or combination of elements in the claim is sufficient to ensure that the claim amounts to significantly more than the judicial exclusion.  But generic computer implementation of an otherwise abstract process does not qualify as "significantly more."  On the other hand, a claimed improvement to a computer or technological process is typically patent-eligible.

    Flesky contended that claim 19 was directed to the abstract idea of "listing word completion candidates based on partial information."  Flesky further made analogies between the claimed invention and the games of Hangman and Wheel of Fortune (i.e., contending that individuals playing these games would create word completion lists in their minds).  Wordlogic countered that Flesky's characterization of the claim was at too high a level.  The Court agreed with Wordlogic.

    The Court acknowledged that procedures for "analyzing information by steps people go through in their minds, . . . without more, [are] essentially mental processes within the abstract-idea category."  Nonetheless, the Court did not acquiesce in Flesky's analogy.  To that point, the Court found "no reasonable scenario in which a mobile device user would type the first letter of a word she wishes to enter, then consult a list of possible completion candidates, then return to entering the text, for she would already know what her intended text was."

    Wordlogic also argued that claim 19 was an improvement to computing systems as it was more efficient and less time consuming than previous text entry mechanisms.  Flesky attempted to take the position that the invention improved the user experience rather than the mobile device upon which it operated, but eventually conceded that virtually any application on a mobile device improves the function of that device.

    Summing things up, the Court wrote that "[i]f less time is required to enter text, then less time is required to operate the device . . . .  Plaintiffs argue, therefore, that claim 19 improves the operation of the device."  Since Flesky failed to rebut this point, the Court ruled that dismissal on the pleadings was premature, and Flesky's motion was denied.

    For better or worse, one of the key aspects of the § 101 analysis post-Alice is whether a challenger can convince the finder of fact that an analogy exists between a claimed procedure carried out on a computer and a previous procedure that had been carried out mentally or manually.  As the Court noted, carrying out the claimed auto-completion procedure mentally makes no sense.  Additionally, while entering text one character at a time arguably existed in analog typewriters, there is no evidence that these devices supported displaying "a plurality of completion candidates" or "selection of a particular completion candidate from among the plurality of completion candidates."

    Furthermore, Wordlogic provided a textbook rebuttal of a patent-eligibility contention.  First, Wordlogic attacked Flesky's shaky step one position, and then established that the claimed invention was an improvement to a computing device under step two.  These arguments, and Flesky's inability to provide a convincing response, won the day.

  • CalendarJanuary 17, 2018 – "Top Patent Law Stories of 2017" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    January 17, 2018 – Customer Partnership Meeting of Technology Center 2600 (U.S. Patent and Trademark Office) – 8:30 am to 4:00 pm (ET)

    January 18, 2018 – "PTAB — A Year in Review" (Foley & Lardner) – 1:00 to 2:00 pm (CST)

    January 18, 2018 – "Strategic Use of Patent Reissue: Whether and When to Pursue a Reissue Application — Correcting Errors, Responding to an IPR Challenge and Mastering the Recapture Rule" (Strafford) – 1:00 to 2:30 pm (EST)

    January 18, 2018 – "IP Year in Review And Look Ahead" – Patent Research (LexisNexis) – 2:00 pm (ET)

    January 19, 2018 – "Paragraph IV Patent Certifications: Recent Legal and Regulatory Developments" (The Knowledge Group) – 12:00 to 1:30 pm (EST)

    January 23, 2018 – "Drafting Software Patents to Survive Section 101 and AIA Challenges — Anticipating and Minimizing the Risk of 101, 103 Rejections, Recent Court Guidance" (Strafford) – 1:00 to 2:30 pm (EST)

    January 25, 2018 – "IP Year in Review And Look Ahead" — Patent Prosecution (LexisNexis) – 2:00 pm (ET)

    January 29, 2018 – "IP Year in Review And Look Ahead" — Patent Drafting (LexisNexis) – 2:00 pm (ET)

    January 31, 2018 – "Paragraph IV Litigation: Best Practices and Practical Tips in 2018" (The Knowledge Group) – 3:00 to 4:00 pm (ET)

    January 31, 2018 – "Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe and China" (Strafford) – 1:00 to 2:30 pm (EST)

    February 21-22, 2018 – Advanced Summit on Life Sciences Patents (American Conference Institute) – New York, NY

    March 5-6, 2018 – Advanced Patent Law Seminar (Chisum Patent Academy) – Houston, TX

    March 8-9, 2018 – Advanced Patent Law Seminar (Chisum Patent Academy) – Cincinnati, OH

  • ACIAmerican Conference Institute (ACI) will be holding its 16th Advanced Summit on Life Sciences Patents on February 21-22, 2018 in New York, NY.  ACI faculty will offer sessions on:

    • Exploring recent developments in case law related to IPRs, especially as they relate to the life sciences
    • Strategies for obtaining patent protection for the latest developments in the life science space
    • Discussions of the § 101 legislative initiatives, recent and pending legislation, and other happenings on the hill
    • Analyzing life-science portfolios for licensing and IP due diligence
    • How to effectively and ethical communicate with the Patent Office

    In particular, ACI's faculty will offer presentations on the following topics:

    • Living Large: Filing and Protecting Big Portfolios while Avoiding Double-Patenting Issues
    • IPR Investigation: Diving into IPR Dos and Don'ts
    • Beyond Sandoz v. Amgen: Future of the Biologics Marketplace and Evolving Biosimilars Development
    • Around the World in 30 Months: Developing a Robust International Portfolio
    • Advancing your Portfolio: Patenting Cutting-Edge Life Sciences Technologies
    • §101 Developments: Exploring Legislative Initiatives
    • Working with the PTO to Obtain (and Extend) Life Sciences Patents
    • Leveraging your Life Sciences Assets: Best Practices for Licensing and IP Due Diligence
    • Anti-Antibody Climate? Pursuing Protection for Antibodies in Today's Environment
    • Ethical Considerations for Prosecuting Life Sciences Patents: Avoiding Inequitable Conduct

    The agenda for the Advanced Summit on Life Sciences Patents can be found here.  A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.

    The registration fee is $2,295.  Patent Docs readers are entitled to a 10% discount off of registration using discount code P10-999-PTD18.  Those interested in registering for the conference can do so here, by e-mailing CustomerService@AmericanConference.com, or by calling 1-888-224-2480.

    Patent Docs is a media partner of ACI's Advanced Summit on Life Sciences Patents.

  • Strafford #1Strafford will be offering a webinar entitled "Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe and China" on January 31, 2018 from 1:00 to 2:30 pm (EST).  Bryan C. Diner and Carla Mouta-Bellum of Finnegan Henderson Farabow Garrett & Dunner, Amy Feng of Wu Feng & Zhang, and Hazel Ford of Finnegan Europe will provide guidance to patent counsel on overcoming the challenges of obviousness in biologics patent claims in the U.S., Europe, and China; will examine the similarities and differences between claim types that have the best chance of success; and will discuss recent case law and key issues that arise.  The webinar will review the following issues:

    • What evidence should counsel provide to support its assertion of nonobviousness in biologics patents?
    • How can counsel overcome the inconsistency in the EPO's treatment of biologics patents?
    • How can patent counsel guide applicants during patent application drafting to reduce the likelihood of rejection?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.